Sutent Europäische Union - Deutsch - EMA (European Medicines Agency)

sutent

pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - antineoplastische mittel - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.

Sunitinib Egis 12,5 mg Hartkapsel Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sunitinib egis 12,5 mg hartkapsel

egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 12,5 mg - sunitinibcyclamat (46316) 18,125 milligramm

Sunitinib Egis 50 mg Hartkapseln Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sunitinib egis 50 mg hartkapseln

egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 50 mg - sunitinibcyclamat (46316) 72,5 milligramm

Sunitinib Egis 25 mg Hartkapseln Deutschland - Deutsch - BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte)

sunitinib egis 25 mg hartkapseln

egis gyógyszergyár zrt. (3332760) - sunitinibcyclamat - hartkapsel - 25 mg - sunitinibcyclamat (46316) 36,25 milligramm